DDA Membership » DDA Member Products & Services » Quality Mark Resources
Currently under development
Oral orforglipron GLP1 (marketed in the USA by Lilly as Foundayo) was authorised for use in weight management and type 2 diabetes in August 2026, in a UK first. In this new DDA podcast, the 12th in our series, DDA Communications Officer Ailsa Colquh
DDA Board Member Dr Ian Hume raised the rural challenges facing dispensing GPs in a Rebuild General Practice campaign roundtable with Liberal Democrat MPs.The discussion focused on the challenges facing GP practices across the country, from rising de
DHSC has published a Tier 2 Medicine Supply Notification (MSN) for lansoprazole 15mg and 30mg orodispersible tablets: limited supply until early January 2027. Up-to-date information abour medicine supply issues can be found in the DHSC and NHSE
